Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications

摘要: Viruses have been shown to be responsible for 10%-15% of cancer cases. Epstein-Barr virus (EBV) is the first associated with human malignancies. EBV can cause many cancers, including Burkett's lymphoma, Hodgkin's post-transplant lymphoproliferative disorders, nasopharyngeal carcinoma and gastric cancer. Evidence shows that phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) plays a key role in EBV-induced The main oncoproteins latent membrane proteins (LMP) 1 LMP2A activate PI3K/Akt pathway, which, turn, affects cell survival, apoptosis, proliferation genomic instability via its downstream target It has also demonstrated activation pathway result drug resistance chemotherapy. Thus, inhibition this increase therapeutic efficacy EBV-associated cancers. For example, PI3K inhibitor Ly294002 effect 5-fluorouracil an line. At present, dual inhibitors mammalian rapamycin used clinical trials may included treatment regimens